Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib (Youdanuo) in Chronic Phase CML
ChiCTR2500103173Phase 4Not yet recruiting
- Sponsor
- The First People's Hospital of Yunnan Province
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by The First People's Hospital of Yunnan Province. Primary endpoint: Complete Hematologic Response (CHR) Rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR2500103173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103173.